CN1823808A - 盐酸克林霉素棕榈酸酯分散片及其制备方法 - Google Patents
盐酸克林霉素棕榈酸酯分散片及其制备方法 Download PDFInfo
- Publication number
- CN1823808A CN1823808A CN 200510057440 CN200510057440A CN1823808A CN 1823808 A CN1823808 A CN 1823808A CN 200510057440 CN200510057440 CN 200510057440 CN 200510057440 A CN200510057440 A CN 200510057440A CN 1823808 A CN1823808 A CN 1823808A
- Authority
- CN
- China
- Prior art keywords
- clindamycin
- palmitate
- hydrochloride
- tablet
- dispersion tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GTNDZRUWKHDICY-DJHAJVGHSA-N Clindamycin palmitate hydrochloride Chemical compound Cl.O1[C@H](SC)[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1[C@@H]([C@H](C)Cl)NC(=O)[C@H]1N(C)C[C@H](CCC)C1 GTNDZRUWKHDICY-DJHAJVGHSA-N 0.000 title claims description 33
- 239000006185 dispersion Substances 0.000 title claims description 33
- 229960000792 clindamycin palmitate hydrochloride Drugs 0.000 title claims description 32
- 238000002360 preparation method Methods 0.000 title claims description 23
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims abstract description 52
- 229960001200 clindamycin hydrochloride Drugs 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 4
- 239000003085 diluting agent Substances 0.000 claims abstract description 3
- 239000000314 lubricant Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims description 35
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 30
- 239000007919 dispersible tablet Substances 0.000 claims description 20
- 229960002227 clindamycin Drugs 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 15
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 15
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 15
- 239000008101 lactose Substances 0.000 claims description 15
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 15
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 14
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000011734 sodium Substances 0.000 claims description 14
- 229910052708 sodium Inorganic materials 0.000 claims description 14
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 13
- 229960000502 poloxamer Drugs 0.000 claims description 13
- 229920001983 poloxamer Polymers 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 241001504664 Crossocheilus latius Species 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 3
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 3
- 239000000686 essence Substances 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 abstract description 3
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- UESHVCAYLZYGOX-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;2-acetyloxybenzoic acid Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC UESHVCAYLZYGOX-FFHNEAJVSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010060968 Arthritis infective Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- -1 compound sulfonamide Chemical class 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100574401A CN100356925C (zh) | 2005-12-14 | 2005-12-14 | 盐酸克林霉素棕榈酸酯分散片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100574401A CN100356925C (zh) | 2005-12-14 | 2005-12-14 | 盐酸克林霉素棕榈酸酯分散片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1823808A true CN1823808A (zh) | 2006-08-30 |
CN100356925C CN100356925C (zh) | 2007-12-26 |
Family
ID=36934748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100574401A Active CN100356925C (zh) | 2005-12-14 | 2005-12-14 | 盐酸克林霉素棕榈酸酯分散片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100356925C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101744833B (zh) * | 2008-12-02 | 2012-05-23 | 济南宏瑞创博医药科技开发有限公司 | 一种治疗细菌性阴道炎的药物组合物 |
CN112402381A (zh) * | 2020-11-19 | 2021-02-26 | 广州一品红制药有限公司 | 一种盐酸克林霉素棕榈酸酯颗粒组合物及其制备方法 |
CN112546000A (zh) * | 2020-12-30 | 2021-03-26 | 海南海神同洲制药有限公司 | 一种盐酸克林霉素棕榈酸酯干混悬剂及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11638759B2 (en) * | 2019-08-13 | 2023-05-02 | Darlene E. McCord | Non-activated, amorphous, pH neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1559431A (zh) * | 2004-02-18 | 2005-01-05 | 重庆凯林制药有限公司 | 盐酸克林霉素棕榈酸酯分散片及其制备方法 |
-
2005
- 2005-12-14 CN CNB2005100574401A patent/CN100356925C/zh active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101744833B (zh) * | 2008-12-02 | 2012-05-23 | 济南宏瑞创博医药科技开发有限公司 | 一种治疗细菌性阴道炎的药物组合物 |
CN112402381A (zh) * | 2020-11-19 | 2021-02-26 | 广州一品红制药有限公司 | 一种盐酸克林霉素棕榈酸酯颗粒组合物及其制备方法 |
CN112546000A (zh) * | 2020-12-30 | 2021-03-26 | 海南海神同洲制药有限公司 | 一种盐酸克林霉素棕榈酸酯干混悬剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100356925C (zh) | 2007-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1149993C (zh) | 莫西沙星药物制剂 | |
CN1297274C (zh) | 药物组合物 | |
CN1946403A (zh) | 氟班色林在治疗经前期及其他女性的性功能障碍中的用途 | |
CN1089471A (zh) | 稳定的延长释放口服组合物 | |
CN1787811A (zh) | 口腔崩解片 | |
CN1212626A (zh) | 含β-内酰胺抗生素的片剂及其制备方法 | |
CN1883456A (zh) | 掩味药物颗粒及其制备方法和用途 | |
CN1823808A (zh) | 盐酸克林霉素棕榈酸酯分散片及其制备方法 | |
CN1903183A (zh) | 替比夫定分散片及其制备方法 | |
CN1203856C (zh) | 盐酸伐昔洛韦分散片及其制备方法 | |
CN1943561A (zh) | 普卢利沙星口腔崩解片及其制备方法 | |
CN1757393A (zh) | 磷霉素钙分散片及其制备方法 | |
CN1817346A (zh) | 苯酰甲硝唑分散片及其制备方法 | |
CN1846702A (zh) | 头孢妥仑匹酯分散片及其制备方法 | |
CN1887277A (zh) | 含有降血脂成分的分散片及其制备方法 | |
CN100336511C (zh) | 口服罗红霉素控释制剂 | |
CN1600313A (zh) | 盐酸头孢他美酯分散片及其制备方法 | |
CN1895250A (zh) | 一种格列喹酮的缓释制剂 | |
CN1297263C (zh) | 葡萄糖酸钙口腔崩解片及其制备工艺 | |
CN1903869A (zh) | 替比夫定的衍生物盐及其制备方法和药物应用 | |
CN1663614A (zh) | 复方氨溴索和头孢菌素类制剂及其应用 | |
CN1634073A (zh) | 左氧氟沙星或其药用盐的口腔崩解片 | |
CN1552327A (zh) | 口服左氧氟沙星控释药物组合物 | |
CN1634014A (zh) | 阿魏酸钠口腔崩解片及其制备工艺 | |
CN1939264A (zh) | 含有头孢他啶的口含制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHONGQING KAIXING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHONGQING CARELIFE PHARMACEUTICAL CO., LTD. Effective date: 20100604 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 400060 NO.2, SHUANGLONG ROAD, CHONGQING CITY ECONOMIC DEVELOPMENT ZONE TO: 400060 NO.2, SHUANGLONG ROAD, CHONGQING CITY ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100604 Address after: 400060 Shuanglong Road 2, Chongqing economic and Technological Development Zone Patentee after: Chongqing Kaixing pharmaceutical LLC Address before: 400060 Shuanglong Road 2, Chongqing Economic Development Zone Patentee before: CHONGQING CARELIFE PHARMACEUTICAL Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU VANKING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHONGQING KAIXING PHARMACEUTICAL CO., LTD. Effective date: 20120518 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 400060 NANAN, CHONGQING TO: 510730 GUANGZHOU, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120518 Address after: 510730 Guangdong Province east of Guangzhou economic and Technological Development Zone No. 6 self building Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Address before: 400060 Shuanglong Road 2, Chongqing economic and Technological Development Zone Patentee before: Chongqing Kaixing pharmaceutical LLC |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Disperse tablet contg. klinemycin hydrochloride palmitate, and its prepn. method Effective date of registration: 20160108 Granted publication date: 20071226 Pledgee: Guangzhou branch directly under the China Co truction Bank Corp. Pledgor: Guangzhou Yipinhong Pharmaceutical Co.,Ltd. Registration number: 2016990000015 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Hanxiong Inventor after: Li Zhenya Inventor after: Lan Zhiyin Inventor after: Li Feng Inventor before: Li Zhenya Inventor before: Lan Zhiyin Inventor before: Li Feng |
|
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20181122 Registration number: 2016990000015 Pledgee after: China Co. truction Bank Corp Guangzhou branch Pledgee before: Guangzhou branch directly under the China Co truction Bank Corp. |
|
PM01 | Change of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190109 Granted publication date: 20071226 Pledgee: China Co. truction Bank Corp Guangzhou branch Pledgor: Guangzhou Yipinhong Pharmaceutical Co.,Ltd. Registration number: 2016990000015 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Disperse tablet contg. klinemycin hydrochloride palmitate, and its prepn. method Effective date of registration: 20190218 Granted publication date: 20071226 Pledgee: China Co. truction Bank Corp Guangzhou branch Pledgor: Guangzhou Yipinhong Pharmaceutical Co.,Ltd. Registration number: 2019440000069 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190426 Granted publication date: 20071226 Pledgee: China Co. truction Bank Corp Guangzhou branch Pledgor: Guangzhou Yipinhong Pharmaceutical Co.,Ltd. Registration number: 2019440000069 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221116 Address after: No.6 Dongbo Road, East District, Guangzhou Economic and Technological Development Zone, Guangdong 510000 Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Patentee after: GUANGDONG ZERUI PHARMACEUTICAL Co.,Ltd. Patentee after: Guangzhou Lianrui Pharmaceutical Co.,Ltd. Patentee after: Guangzhou Runlin Pharmaceutical Technology Co.,Ltd. Patentee after: Euphorbia Biological Medicine Co.,Ltd. Address before: 510730 Building 1, No.6 Dongbo Road, Guangzhou Economic and Technological Development Zone, Guangdong Province Patentee before: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |